Decades of investigative research have made surprisingly little headway in elucidating the biological underpinnings of CUP. Early clinical trials, which leveraged cutting-edge technologies such as gene-expression profiling, sought to pinpoint the tissue of origin (ToO) with the promise that targeted, primary-site-specific treatment would outperform non-selective chemotherapy. Yet, these initial randomized trials yielded disappointing results, failing to demonstrate a statistically significant improvement in patient survival. These findings raised fundamental questions about the intrinsic nature of CUP, suggesting that a histology-guided therapeutic approach might be insufficient to produce meaningful clinical gains.

However, the landscape of CUP diagnosis and management is witnessing a paradigm shift fueled by rapid advances in molecular oncology and precision medicine. Large-cohort randomized studies have brought groundbreaking evidence that therapies guided by molecular profiling—whether agnostic of tissue origin or based on the identification of a specific primary tumor site—can extend survival and improve patient quality of life. The integration of comprehensive genomic profiling, including next-generation sequencing (NGS) to detect actionable mutations, is enabling oncologists to personalize treatment strategies for CUP patients in ways previously unattainable.

In parallel to these genomic approaches, immunotherapy has emerged as a promising avenue for patients with CUP, particularly for those whose disease is refractory to or recurs following standard chemotherapeutic regimens. The deployment of immune checkpoint inhibitors, drugs designed to unleash the immune system’s capacity to recognize and destroy cancer cells, is transforming therapeutic outlooks even in the absence of a known primary tumor. Phase II clinical trials suggest durable responses can be achieved in subsets of patients, supporting the notion that CUP may harbor unique immunogenic features amendable to immune modulation.

Modern diagnostic methodologies for CUP are no longer limited to traditional histopathological techniques. DNA and RNA sequencing advancements permit comprehensive molecular characterization of metastatic lesions, while DNA methylation profiling offers epigenetic signatures that aid in tumor classification. Additionally, the analysis of circulating tumor DNA (ctDNA) extracted from blood samples provides a minimally invasive strategy to detect and monitor actionable mutations in real time. These approaches, combined with artificial intelligence-driven pathology analyses, are evolving diagnostic paradigms, offering nuanced insights into tumor biology and origin.

Artificial intelligence (AI) applications in pathology represent a particularly exciting frontier for CUP diagnostics. Machine learning algorithms trained on vast datasets can analyze complex patterns within histological slides, integrate molecular data, and predict tissue of origin with increasing accuracy. This technology’s ability to synthesize multi-omic layers could soon redefine CUP characterization, freeing clinicians from dependence on often ambiguous morphological assessments and enabling more confident, data-driven treatment decisions.

Despite the scientific and technological breakthroughs, the clinical management of CUP remains highly debated regarding whether treatment should continue to be guided by inferred tissue origin or if a more histology-agnostic precision oncology approach is warranted. Advocates for a tissue-specific strategy argue that identifying the primary tumor type allows for the application of well-established, evidence-based treatments tailored to that cancer’s biology. Conversely, proponents of a histology-agnostic paradigm highlight the success of molecularly guided therapies targeting oncogenic drivers regardless of cancer lineage—a principle exemplified by FDA approvals of several site-agnostic drugs.

The question of treating CUP as a model for precision oncology touches upon broader themes in cancer research. CUP arguably epitomizes the ultimate expression of metastatic heterogeneity, posing conditions where conventional classification fails and molecular therapeutics may hold the greatest promise. This has ignited interest in developing therapeutic algorithms based on tumor molecular landscapes rather than anatomical origin, potentially influencing treatment paradigms well beyond CUP itself. The lessons learned from CUP could thus catalyze innovations applicable to numerous malignancies with complex metastatic profiles.

Notwithstanding these advancements, the field recognises significant challenges and areas in need of further research. The reproducibility and standardization of molecular diagnostic platforms across institutions remain hurdles to widespread clinical adoption. Moreover, understanding the full spectrum of genomic alterations capable of guiding therapy in CUP patients is an evolving endeavor complicated by the genetic heterogeneity within and between tumors. Additionally, integrating immune profiling to predict response to checkpoint inhibitors requires larger, controlled studies to establish validated biomarkers.

From a therapeutic standpoint, the implementation of personalized medicine in CUP care demands multidisciplinary collaboration among oncologists, pathologists, molecular biologists, and bioinformaticians. Care pathway redesigns to include early molecular testing and expanded access to targeted agents are crucial for translating scientific gains into improved patient outcomes. Economic considerations also play a role, as next-generation sequencing and immunotherapies can be resource-intensive, necessitating health policy interventions to ensure equitable treatment availability.

The evolving evidence base supports a future where CUP management straddles the dual axes of molecular precision and clinical pragmatism. For patients, this may translate to more frequent use of molecular profiling assays at diagnosis and during treatment, informed selection of targeted therapies based on actionable mutations, and opportunistic inclusion in immunotherapy trials. Such integrated strategies hold promise not only to extend survival but also to reduce toxicity compared with traditional chemotherapeutics.

In summary, cancer of unknown primary, once a diagnostic and therapeutic quagmire, is increasingly illuminated by advances in molecular diagnostics, artificial intelligence, and targeted therapies. The integration of multi-omic profiling with emerging immunotherapeutic approaches is enabling a transition from generalized chemotherapy to precision oncology tailored to the molecular architecture of individual tumors. As clinical trials continue to validate these strategies, CUP may soon become a beacon case for histology-agnostic treatment modalities—a testament to the transformative potential of precision medicine in oncology.

The scientific community eagerly anticipates further breakthroughs that will unravel the biological intricacies of CUP, optimize molecular diagnostic workflows, and refine treatment algorithms. Such progress will require concerted efforts in clinical research, data integration, and resource allocation. Ultimately, the vision is to convert CUP from a diagnostic challenge with dismal prognosis into a model disease of personalized, effective, and durable cancer care—a milestone that could reshape oncological practice in the coming decade.

Subject of Research: Cancer of Unknown Primary (CUP): diagnostic methodologies and therapeutic strategies including molecular profiling and immunotherapy.

Article Title: Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.

Article References:
Pouyiourou, M., Bochtler, T., Pauli, C. et al. Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01060-8

Image Credits: AI Generated

Metastatic colorectal cancer remains a formidable clinical challenge, often characterized by late diagnosis and poor survival rates. Traditionally, the enumeration of circulating tumour cells — cancer cells that have shed from the primary tumour into the bloodstream — has emerged as a robust prognostic indicator. The innovative angle of this new study lies in coupling CTC counts with the expression profiles of selected messenger RNAs (mRNAs) and microRNAs (miRNAs) in whole blood, aiming to decode more nuanced molecular signals that could refine patient risk stratification.

The researchers conducted a comprehensive analysis involving 151 patients who were previously screened for enrollment in two clinical trials, VISNÚ1 and VISNÚ2. Using real-time quantitative PCR (qPCR), the team quantified the expression of specific RNAs implicated in metastasis directly from whole blood samples. The study employed the CellSearch system — an FDA-approved technology — to accurately enumerate basal circulating tumour cells (bCTCs), focusing on their potential correlations with RNA expression, tumour genetic mutations, and clinical outcomes.

One of the most salient findings was the significant association between bCTC count and the expression of AGR2 mRNA. AGR2, or anterior gradient 2, is a protein linked to tumour growth and metastatic potential, and its elevated mRNA levels in the blood appear entwined with the burden of circulating tumour cells. This correlation was consistent across the entire patient cohort, underscoring AGR2’s potential as a systemic biomarker reflective of tumour dissemination.

The study further delved into subgroups, revealing that AGR2, alongside ADAR1 and LGR5, showed significant associations with bCTC numbers in patients harboring three or more circulating tumour cells. ADAR1, an RNA editing enzyme, has been recognized for its roles in cancer immune evasion and RNA stability, while LGR5 is known as a stemness marker indicative of cancer cell self-renewal. The simultaneous link between these RNAs and higher bCTC counts suggests a complex interplay between tumour biology, stem cell-like properties, and metastatic dissemination.

Interestingly, when focussing on tumours with wild-type (native) RAS, BRAF, and PIK3CA genes, the correlation between these RNA biomarkers and CTCs remained prominent, highlighting their potential utility in a specific genetic context. By contrast, in patients with mutations in these oncogenes, the relationships shifted. No direct associations with bCTC counts emerged; instead, an intriguing pattern of RNA expression changes was observed.

Specifically, mutated tumours showed an upregulation of miR-224-5p and LGR5, denoting enhanced stemness features and possibly increased metastatic competence. Simultaneously, there was a downregulation of CD274, coded as PD-L1, an immune regulatory molecule crucial in cancer’s evasion of immune surveillance. These alterations underscore the distinct biological pathways active in genetically mutant tumours and may have implications for tailoring immunotherapeutic approaches.

A major highlight of the study was the revelation that lower blood levels of miR-106a-5p and miR-26a-5p microRNAs were significantly associated with shorter overall survival. These miRNAs—which regulate gene networks involved in cell proliferation and apoptosis—could serve as independent prognostic markers beyond traditional clinical and pathological factors. Their robust association with poor prognosis, confirmed through multivariate statistical analyses, opens a window for new blood-based assays to predict patient outcomes.

The integration of whole blood RNA profiling with CTC enumeration embodies a novel analytical framework that could revolutionize the monitoring and management of metastatic colorectal cancer. By capturing both circulating tumour burden and molecular signatures simultaneously, this approach offers a dynamic picture of tumour biology in real-time, surpassing the limitations of tissue biopsies that often fail to reflect tumour heterogeneity and evolution.

Moreover, the implications extend to personalized medicine. Understanding how RNA biomarkers correlate with mutational status offers clues to the underlying tumorigenic mechanisms, potentially guiding targeted therapeutic decisions. For example, identifying patients with elevated AGR2 and LGR5 in the context of wild-type mutational status may prioritize them for treatments that disrupt cancer stemness or metastatic seeding.

The findings also contribute to a growing body of evidence linking microRNAs to cancer prognosis, resistance, and metastasis. MicroRNAs like miR-106a-5p and miR-26a-5p are emerging as vital modulators of oncogenic pathways, and their circulating levels are conveniently accessible for non-invasive monitoring. Future studies can explore whether modulating these miRNAs therapeutically could alter disease trajectory.

This study’s design, anchored by data from prospective clinical trials (NCT01640405 and NCT01640444), lends robustness and clinical relevance to the conclusions. The researchers meticulously validated RNA expression and CTC counts, linking molecular phenomena to clinical endpoints, thus reinforcing the translational value of their discoveries.

Despite the promise, challenges remain. The sensitivity and specificity of RNA biomarkers in heterogeneous patient populations need further validation across diverse cohorts and clinical settings. Additionally, deciphering the causal relationships between RNA expression, mutational landscapes, and tumour dissemination demands longitudinal studies and functional assays.

Nevertheless, this integrative approach exemplifies the future of oncology research, where multifaceted biomarkers combine to capture the complexity of cancer progression. The potential to stratify patients accurately based on blood RNAs and CTCs could facilitate adaptive treatment algorithms, improving survival and quality of life for many facing metastatic colorectal cancer.

As efforts accelerate towards liquid biopsies in oncology, the identification of AGR2, ADAR1, LGR5, miR-224-5p, miR-106a-5p, and miR-26a-5p as critical blood-based markers heralds a new era of precision diagnostics. Their clinical deployment could enable oncologists to detect aggressive disease early, monitor therapeutic response dynamically, and intervene promptly.

The study ultimately underscores the heterogeneity of metastatic colorectal cancer and the importance of personalized molecular profiling. As the landscape of cancer treatment becomes increasingly tailored, insights derived from circulating biomarkers promise to enhance prognostication and guide innovative therapies that could change the course of this deadly disease.

Looking forward, integrating such RNA biomarkers into clinical workflows hinges on developing standardized assays and platforms amenable to routine practice. Collaborations between researchers, clinicians, and diagnostic companies will be pivotal to translate these findings from bench to bedside.

In conclusion, this landmark research represents a significant leap towards understanding the molecular underpinnings of circulating tumour cells and RNA biomarker signatures in metastatic colorectal cancer. By illuminating previously uncharted interactions between circulating biomarkers and cancer genetics, the study opens pathways to novel diagnostic approaches, better patient stratification, and ultimately improved clinical outcomes.

Subject of Research: Associations between blood RNA biomarkers, circulating tumour cells, tumour mutations, and prognosis in untreated metastatic colorectal cancer patients

Article Title: Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer

Article References:
Valladares-Ayerbes, M., Toledano-Fonseca, M., Graña, B. et al. Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer. BMC Cancer 25, 743 (2025). https://doi.org/10.1186/s12885-025-14098-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14098-9